Streetbeat News

Stock Prices

RDHL

Redhill Biopharma shares are trading higher following the announcement of positive results from multiple in vivo studies.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:12 pm

SBFM

Sunshine Biopharma (NASDAQ:SBFM) reported Q2 earnings per share (EPS) of $(9.94), significantly missing the analyst estimate of $(0.37). However, the company reported sales of $9.30 million, beating the estimate of $9.00 million.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:12 pm

LZM

Lifezone Metals (NYSE:LZM) reported a Q3 2024 GAAP EPS of $(0.14), missing the analyst consensus estimate of $(0.05) by 180%.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:11 pm

TNXP

Tonix Pharmaceuticals shares are trading higher following the company's Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:11 pm

AMAT

DELL

FSTR

MCHP

TSLA

Top Wall Street analysts with high accuracy rates have made recent stock picks. William Stein from Truist Securities sees a 1% downside in Tesla (TSLA). Aaron Rakers from Wells Fargo sees a 35% upside in Dell Technologies (DELL). Sidney Ho from Deutsche Bank sees an 11% upside in Applied Materials (AMAT). Alex Rygiel from B. Riley Securities sees an 11% gain in L.B. Foster (FSTR). Harsh Kumar from Piper Sandler sees a 24% upside in Microchip Technology (MCHP).

Portfolio Pulse from Avi Kapoor

August 19, 2024 | 12:09 pm

ALZN

Alzamend Neuro shares are trading higher following the announcement of a partnership with Massachusetts General Hospital to conduct a Phase II clinical study of AL001 for PTSD treatment.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:08 pm

ABL

Abacus Life, Inc. (NASDAQ: ABL) and Lorisco Life LLC have announced the launch of PREADISAN™, a health prediction platform that uses machine learning and proteomics to improve health predictions. This partnership aims to enhance Abacus' longevity and actuarial technology services by providing more personalized risk scores.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:06 pm

PHAT

Phathom Pharmaceuticals has priced an offering of 8.7 million shares and 2.6 million pre-funded warrants at $11.50 per share, raising approximately $130 million.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:02 pm

PCSA

Processa Pharmaceuticals (NASDAQ: PCSA) reports positive preclinical data for its Next Generation irinotecan (NGC-Iri), showing it delivers more cancer-killing SN-38 molecules to tumors with fewer side effects compared to irinotecan and Onivyde. The studies suggest NGC-Iri could be a more effective and safer cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:02 pm

LDTC

LeddarTech Holdings Inc. (NASDAQ: LDTC) announced a financing agreement with principal shareholders and senior lender for up to $9 million in bridge loans. FS Investors and Investissement Québec have the option to convert their loans into common shares at a premium price. Additionally, FS will convert $1.5 million of existing convertible notes into shares at $2.00 per share.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:01 pm